c-myc in ABPC45 occurred via a multistep switch region-mediated process and that a reciprocal translocation has indeed taken place. Unlike many other plasmacytomas, this event did not interrupt the normal c-myc transcription unit. Rather, disruption of gene regulation is manifested in part by a change in relative usage of the two promoters normally used by the unrearranged gene. In contrast to several of its counterparts in Burkitt lymphomas, DNA sequence analysis of the translocated c-myc gene of ABPC45 reveals that it has not acquired point mutations in the noncoding first exon. These results strongly imply that a cis-acting regulatory element normally located 5' of exon 1 is lost and that heavy-chain constant region or enhancer sequences exert similar cis effects on translocated c-myc loci.
Plasmacytomas induced in BALB/c or NZB mice frequently possess rcpt (12;15) or (6;15) . These translocations occur near the c-myc oncogene on chromosome 15 and juxtapose this gene and the immunoglobulin heavy-chain (IgH) constant region (CH) locus on chromosome 12 or the K light-chain locus on chromosome 6 (1, 2). The (12;15) and (6;15) translocations are termed typical and variant, respectively, based on their relative frequencies among tumors studied. It is generally accepted that activation of the c-myc gene as a result of its translocation to the immunoglobulin gene loci contributes to the development of malignant phenotype in tumors of the B-cell lineage, although the precise role of this gene in the transformation process as well as its function in normal cells remain to be elucidated.
In those tumors that have undergone rcpt (12;15) , the c-myc gene is frequently broken-i.e., recombination has occurred within the gene (3) (4) (5) . Breakage ofthis type does not alter the amino acid coding potential of c-myc because the breaks occur within the noncoding first exon or first intron. Although the gene's two normal promoters are removed by such recombination, production of truncated transcripts containing the two protein coding exons occurs from normally silent promoters in the intron (5). These observations led to proposals that c-myc expression was normally under negative regulation by first exon sequences and that removal of these putative control elements by gene breakage and translocation leads to constitutively deregulated expression (6, 7) . It has also been proposed that the instability of full-length c-myc mRNA in vivo is related to the presence of first exon sequences (8) . Thus, it is possible that truncated transcripts are not subject to normal post-transcriptional control. These hypotheses tend to be supported by the observation that c-myc exon 1 has undergone extensive mutation in several translocated but unbroken genes cloned from Burkitt lymphomas (9) . More recently, however, examples of retroviral insertion 5' of c-myc (10) and variation in a pattern of DNase I-hypersensitive sites in the 5' flanking regions of c-myc in various genomic contexts (11) have been described. These results suggest a potential role for regions 5' of c-myc in transcriptional regulation.
In this communication, we report the cloning and extensive molecular analysis of the rearranged c-myc gene from ABPC45, a plasmacytoma induced by pristane and Abelson murine leukemia virus (12) . This tumor lacks cytogenetically detectable translocation, but it has undergone a hemizygous interstitial deletion of chromosome 15 (12) . We found, however, that a series of switch (S) region-mediated recombinations has occurred between chromosomes 12 and 15, leaving the IgH enhancer (13, 14) -2.5 kilobase pairs (kbp) 5' of c-myc. Alteration of c-myc transcriptional control is reflected by a change in the normal pattern of promoter usage. DNA sequence analysis shows that the translocated gene has not undergone mutations in the first exon, although several point mutations may exist in the 5' flanking region.
MATERIALS AND METHODS
Molecular Cloning, A 14.8-kbp EcoRI fragment containing the rearranged c-myc gene of ABPC45 was partially purified by preparative agarose electrophoresis of restricted genomic DNA and cloned in the bacteriophage vector EMBL 4 (15) .
DNA Blotting and Sequencing. Genomic DNAs were prepared and analyzed by Southern blotting as described (16) .
Abbreviations: bp, base pair(s); kbp, kilobase pair(s); IgH, immunoglobulin heavy chain; CH, heavy-chain constant region; S, heavychain switch region.
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Sequencing was accomplished by the dideoxy-chain termination method, using M13 vectors (17) .
Si Nuclease Mapping. A clone consisting of a 700-base-pair (bp) EcoRI*/BamHI fragment of c-myc 5' flanking and exon 1 sequences (18) and a 394-bp BamHI/Sst I fragment from exon 1 was constructed in M13 mplO. This clone was used to prepare a uniformly labeled single-stranded probe for S1 nuclease mapping (5) . Samples typically contained 2 x 104 cpm of probe and 2 pug of poly(A)+ RNA; they were prepared and analyzed as described (18) .
RESULTS
Multiple S Region Recombinations Contributed to the ABPC45 c-myc Rearrangement. The 14.8-kbp EcoRI fragment containing the rearranged c-myc gene of ABPC45 was cloned from genomic DNA. Fragments of DNA representing the gene's 5' flanking region were subcloned and used to probe Southern blots of DNAs from somatic cell hybrids containing defined mouse chromosomes on a hamster background (16) . Contrary to our expectations, we found that this portion of the clone contained chromosome 12-specific DNA. Furthermore, the chromosome 12 DNA was determined to be composed of two segments that were not in germ-line context with respect to each other (data not shown).
Initial DNA sequence data obtained from the ABPC45 c-myc clone strongly suggested that immunoglobulin a S region (Sj) sequences were involved in this rearrangement, 5 ' flanking c-myc DNA that has persisted in the genome of this tumor by virtue of its having participated in a reciprocal translocation. As expected, a DNA probe consisting of -7 kbp of 5' flanking c-myc sequences hybridized intensely to this reciprocal fragment (data not shown).
The Igh Enhancer Lies 5' of c-myc in ABPC45. Although the c-myc clone shown in Fig. 1 does not contain the IgH enhancer, we were able to show by genomic Southern blotting that this regulatory element lies in the predicted position -2.5 kbp 5' of exon 1. As shown in Fig. 3 , BamHI and Bgl II digests ofABPC45 DNA yield fragments of4.8 and 4.7 kbp, respectively, which hybridize to both c-myc and enhancer probes. EcoRI, which cuts the genomic DNA between the regions expected to hybridize to these probes, does not yield such a comigrating band.
Context of Other Ig CH Genes in ABPC45. respectively. ABPC45 was compared with BALB/c spleen and ABPC26, which, like ABPC45, was classified as translocation negative and appears to possess a band deletion on chromosome 15 (12) . In contrast to ABPC45, however, ABPC26 has not been shown to have a detectable rearrangement 5' of c-myc. Densitometric tracings were derived from the autoradiographs shown in Fig. 5 and were used to calculate the ratios of promoter usage shown in Table 1 . We find that the more 5' promoter (P1) is relatively favored in ABPC45 compared with the spleen control and ABPC26. This quantitative analysis demonstrates that c-myc mRNA levels in the two tumors are increased relative to spleen and that the presence of the IgH enhancer near c-myc in ABPC45 does not result in higher steady-state levels of this transcript than in a cytogenetically analogous tumor that appears to lack such a rearrangement.
DISCUSSION
We have completed a detailed molecular characterization of the translocated c-myc gene from a tumor initially believed to be translocation negative. Data presented here leads us to conclude that an unusual two-step process occurred and that the first event was a rcpt (12;15) that involved S,. As shown in Fig. 3 , the putative reciprocal EcoRI fragment is 9.5 kbp, compared with a predicted size of 12.6 kbp if a precise rcpt (12;15) occurred ( Fig. 1 A and D) . Thus, we suggest that ---3 kbp of DNA was deleted as a consequence of translocation, a commonly observed feature of these recombination events (18), which spans the 5' portion of exon 1 and -580 bp of germ-line 5' flanking sequence. The enhancer probe was the 680-bp EcoRI/Xba I fragment containing the IgH enhancer (14) subcloned from pJ11 (23) . (18, 24) . Furthermore, it is likely that this deletion occurred in the Sa region, because the narrowly defined c-myc 5' probe is able to detect the putative reciprocal product. Our observations are therefore consistent with typical head-to-head recombination of c-myc with Sa that was followed by a second recombination event, either with the initial reciprocal chromosome or with another copy of chromosome 12. In mechanism, this may resemble a previously described multistep rearrangement in a plasmacytoma involving chromosomes 6, 12, and 15 (25) . The second event occurred in a tail-to-tail manner, resulting in an inversion of the two IgH segments, which reside 175 kbp apart in germ-line DNA (26) , with respect to each other and leaving the IgH enhancer =2.5 kbp 5' of c-myc. It is possible that the presence of the band deletion on chromosome 15 is somehow related to this secondary rearrangement. Indeed, the detection of only cytogenetically normal copies of chromosome 12 in ABPC45 (12) suggests that the rearranged c-myc ofABPC45 resides on a "del 15" chromosome. Our data do not exclude other possibilities-for example, paracentric inversion of the CH locus prior to invasion by c-myc. This seems unlikely, however, because it has no known precedent and Southern blotting does not reveal another product that would be predicted to arise from such an inversion (i.e., CA and Ca linked head to head) (see Fig. 4 ).
The positioning of the IgH enhancer 5' of c-myc by an apparently S region-mediated mechanism is extremely interesting and unusual. There are examples of Burkitt lymphomas in which c-myc recombined 5' of the enhancer (a region devoid of switch sequences) in a head-to-head manner (11, 27) . Among plasmacytomas, there is one example, ABPC17, in which the IgH enhancer was inserted by a mechanism tail-to-head 5' of c-myc (unpublished results). The possibility that a small segment of DNA carrying IgH enhancer was inserted 5' of c-myc is precluded by our data, specifically the lack of a common EcoRI fragment in ABPC45 DNA that hybridizes to both the enhancer and c-myc probes (see Fig.  3 ).
DNA sequence analysis defined the chromosomal recombination site to be -365 bp 5' ofc-myc exonl in ABPC45. This is in agreement with the clustering of translocation breakpoints 5' of c-myc in other plasmacytomas and further supports our contention that a cis-acting regulatory element is located =350 bp of more 5' of c-myc (unpublished results). The loss or disruption of this upstream region could be a major factor in the abnormal constitutive expression ofc-myc in most plasmacytomas. Comparison of the ABPC45 S1 nuclease mapping data with that of another tumor that lacks a c-myc rearrangement suggests that transcriptional control is disrupted by translocation immediately 5' of c-myc and that one manifestation of this is the relatively greater usage of P1. Promoter shifts of variable magnitude (P1/P2 = 0.85-2.6) have been found in 40%o of plasmacytomas that have intact c-myc genes (unpublished results). This variation may be a consequence of multiple regulatory elements influencing the Fig. 2; positions -100 to -300) whose sequence was obtained from data previously published by other investigators (21) . We have also found a 9-bp inverted repeat just 5' of the recombination site and a segment of DNA from the 5' flanking region that shares a 12/15 homology with the extreme 5' portion of exon 1 (see Fig. 2 ). The DNA between the latter two segments includes the translocation breakpoints of ABPC45 and five other plasmacytomas (unpublished results) and it is in a region that has substantial sequence homology with human c-myc (11, 21) .
The fact that c-myc frequently recombines within the CH locus in plasmacytomas but rarely involves the IgH enhancer suggests that some other property of these genes or their environment is capable of exerting a positive regulatory influence on the oncogene. Indeed, it has been shown that this enhancer is not an absolute requirement for efficient heavy-chain gene expression (29, 30) . It also appears that an undefined cis defect may be capable of preventing expression of a functionally rearranged C, gene that is normal with respect to all previously described transcriptional regulatory elements (31) . Taken together, these data could imply that the Cc gene that we suspect was the initial target of c-myc translocation in ABPC45 may have had (or subsequently acquired) some cis defect for which the IgH enhancer could compensate.
Note Added in Proof. The insertion of the IgH enhancer of 5' of c-myc in ABPC17 has recently been published (32) . Interestingly, the chromosome 15 breakpoint in this tumor is identical to that in ABPC45.
